Bright Minds Biosciences Inc (DRUG) Stock Price, Quote & News

Company Profile

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 647 865 8622

Website: brightmindsbio.com

Address:

19 Vestry Street, New York, United States

Rampageusa May. 12 at 9:55 PM

$WOK eventually this low floaters can do weird 100/200 like few others did $DRUG, $SMX ..many to name

1 · Reply

Aaronwasinger May. 12 at 2:35 PM

$DRUG $ERNA $TC

0 · Reply

CarlPhilipTrading May. 12 at 2:34 PM

$TC will go huge like $ERNA or $DRUG in 2024. TC super low float ww

0 · Reply

Rampageusa May. 8 at 5:32 PM

$AEHL the way they are playing seems 1000% ah hrs to 5/with multiple long halts till 3.00pm close..my opinion as I have seen such things for $DRUG and other tickers jn history..

0 · Reply

TheRealShortSqueezy May. 8 at 3:15 PM

🔎 Before You Invest: Check the Dilution 👇 If you invest in small caps, biotech, or growth companies, one of the biggest risks is share dilution, and many investors don’t notice it until it’s too late. That’s where http://DilutionTracker.com becomes incredibly useful. 📊 DilutionTracker helps investors quickly analyze: ➡️ Company financial data ➡️ SEC filings and disclosures ➡️ Share structure and potential dilution ➡️ Warrants, options, and convertible securities ➡️ Capital raises and funding history Instead of digging through dozens of filings manually, DilutionTracker organizes the information in a way that makes it much easier to see how a company is financing itself and how it might impact shareholders. Learn more: https://dilutiontracker.com $WOLF $DFDV $NXTT $QUBT $DRUG

0 · Reply

tupelo3 May. 7 at 9:42 PM

$DRUG anyone find it strange that $DRUG is providing earnings on a Friday after the close?

0 · Reply

BodhiJR May. 7 at 7:50 PM

$OPEN It is TIME....the $GME $DRUG and $CAR MOVE is happening “It was never about money for us it was about us against the system.” Bohdi 🔥🏦🤙🏽 https://x.com/nejatian/status/2052421954154762575?s=46

0 · Reply

Taylormax May. 7 at 10:57 AM

$LGHL I'm bullish on this stock! Purely based on logic. The market cap is low like $DRUG and $HCAI it blew the market out the water! It's a real company backed by Crypto. People who shorted this will be burned soon.

0 · Reply

Trick2MoneyisHavingSum May. 5 at 11:47 AM

$SDOT .529 vwap, then 1 billion traded $DRUG $NUKK

0 · Reply

InvestingSpaceman May. 4 at 9:35 PM

$HKD $DRUG $GME

0 · Reply

DRUG Initiates Coverage On Bright Minds Biosciences -- Price Target Announced

2026-04-12T23:20:16.000Z - 4 weeks ago

Bright Minds initiated with a Buy at Jefferies

2026-03-04T20:00:37.000Z - 2 months ago

Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript

Mar 4, 2026, 9:10 AM EST - 2 months ago

Bright Minds Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T13:39:47.000Z - 2 months ago

Bright Minds price target raised to $145 from $115 at H.C. Wainwright

Wed, 25 Feb 2026 16:30:00 -0500 - 2 months ago

Bright Minds Biosciences to Present at Upcoming Conferences

2026-02-17T11:31:20.000Z - 3 months ago

BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News

2026-02-13T14:21:13.000Z - 3 months ago

Bright Minds price target lowered to $126 from $142 at Baird

Fri, 09 Jan 2026 11:56:00 -0500 - 4 months ago

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

2026-01-08T07:57:10.000Z - 4 months ago

Bright Minds Biosciences (DRUG) Prices $175M Public Offering

Wed, 07 Jan 2026 21:33:00 -0500 - 4 months ago

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

2026-01-07T13:05:22.000Z - 4 months ago

Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

2026-01-07T13:00:57.000Z - 4 months ago

Bright Minds price target raised to $142 from $82 at Baird

2026-01-07T11:46:42.000Z - 4 months ago

Bright Minds price target raised to $147 from $72 at BTIG

2026-01-06T21:11:24.000Z - 4 months ago

Bright Minds announces $100M common shares offering

Tue, 06 Jan 2026 16:00:00 -0500 - 4 months ago

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

2026-01-06T18:31:59.000Z - 4 months ago

BTIG Raises Price Target for Bright Minds Biosciences (DRUG) to $147 | DRUG Stock News

2026-01-06T18:00:09.000Z - 4 months ago

Bright Minds Biosciences Inc BMB-101 Topline data announcement Transcript

Tue, 06 Jan 2026 11:52:33 -0500 - 4 months ago

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

2026-01-06T15:07:53.000Z - 4 months ago

Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday

2026-01-06T13:00:04.000Z - 4 months ago

Bright Minds Biosciences (DRUG) Surges on Successful Trial Results

Jan 6, 2026, 8:00 AM EST - 4 months ago

Bright Minds Biosciences Transcript: Study Result

2026-01-06T12:25:21.000Z - 4 months ago

Bright Minds announces results from Phase 2 BREAKTHROUGH trial of BMB-101

Tue, 06 Jan 2026 07:16:00 -0500 - 4 months ago

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

2026-01-06T09:04:44.000Z - 4 months ago

Bright Minds To Unveil Topline Results For BMB-101 Phase 2 Trial In Absence Seizures And DEE

Mon, 05 Jan 2026 16:30:00 -0500 - 4 months ago

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

2026-01-02T13:30:17.000Z - 4 months ago

Bright Minds Biosciences (DRUG) Maintains Buy Rating with $80 Price Target | DRUG Stock News

2025-12-30T16:00:54.000Z - 4 months ago

Bright Minds Biosciences (DRUG) Sees Stable Analyst Rating Today | DRUG Stock News

Tue, 25 Nov 2025 16:30:00 -0500 - 6 months ago

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

2025-11-25T14:55:03.000Z - 6 months ago

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet

2025-11-17T22:29:36.000Z - 6 months ago

Why Bright Minds Biosciences Stock Topped the Market on Monday

Mon, 17 Nov 2025 06:50:00 -0500 - 6 months ago

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

2025-11-15T01:53:30.000Z - 6 months ago

Sio Capital Management, LLC Reduces Stake in Bright Minds Biosciences Inc

Nov 12, 2025, 9:00 AM EST - 6 months ago

Bright Minds Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T12:25:38.000Z - 6 months ago

Bright Minds price target raised to $82 from $75 at Baird

Nov 6, 2025, 10:00 AM EST - 6 months ago

Bright Minds Biosciences Transcript: KOL Event

Thu, 06 Nov 2025 06:30:00 -0500 - 6 months ago

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

2025-10-15T12:50:03.000Z - 7 months ago

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

2025-09-18T13:55:01.000Z - 8 months ago

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

2025-09-15T12:33:59.000Z - 8 months ago

Bright Minds Biosciences (DRUG) Maintains 'Buy' Rating with $85 Price Target | DRUG Stock News

2025-09-08T17:54:11.000Z - 8 months ago

Large Patient Population Is Key Driver For Bright Minds' Growth

2025-09-08T09:55:04.000Z - 8 months ago

Bright Minds initiated with a Buy at BTIG

2025-09-05T10:56:42.000Z - 8 months ago

Bright Minds Biosciences (DRUG) Launches $100 Million ATM Offering

2025-09-05T00:00:00.000Z - 8 months ago

BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING

2025-09-04T12:35:25.000Z - 8 months ago

Bright Minds says BMB-201 outperforms sumatriptan in preclinical model

2025-07-02T10:45:41.000Z - 11 months ago

Bright Minds assumed with an Overweight at Cantor Fitzgerald

DRUG

Tue, 20 May 2025 08:00:00 -0400 - 1 year ago

Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025

Wed, 07 May 2025 16:45:18 -0400 - 1 year ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

2025-05-07T20:45:18.000Z - 1 year ago

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Mon, 28 Apr 2025 08:00:00 -0400 - 1 year ago

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Jan 7, 2025, 6:50 AM EST - 1 year ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Nov 4, 2024, 2:41 PM EST - 1 year ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Oct 28, 2024, 8:21 AM EDT - 1 year ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 18, 2024, 6:50 AM EDT - 1 year ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 16, 2024, 10:45 AM EDT - 1 year ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 16, 2024, 5:57 AM EDT - 1 year ago

Biotech stock tumbles after unexplained 1,446% gain

Oct 15, 2024, 9:09 PM EDT - 1 year ago

Bright Minds is Unaware of Any Material Changes

Oct 3, 2024, 9:00 AM EDT - 1 year ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Sep 19, 2024, 10:00 AM EDT - 1 year ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 12, 2024, 8:00 AM EDT - 1 year ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Aug 8, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 12, 2023, 10:33 AM EDT - 3 years ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 11, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Announces Effective Date of Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Announces Proposed Share Consolidation

Apr 19, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 10, 2023, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Feb 27, 2023, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 17, 2023, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 8, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Jan 27, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 9, 2023, 4:05 PM EST - 3 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Dec 2, 2022, 7:07 PM EST - 3 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 3 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 23, 2022, 11:35 AM EST - 3 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Sep 7, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Aug 31, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 30, 2022, 3:35 PM EDT - 4 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 23, 2022, 9:07 PM EDT - 4 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 4 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Aug 18, 2022, 3:34 PM EDT - 4 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Jun 27, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

May 12, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 2, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Apr 19, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

Mar 14, 2022, 6:50 AM EDT - 4 years ago

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Mar 8, 2022, 7:30 AM EST - 4 years ago

Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference

Dec 6, 2021, 6:50 AM EST - 4 years ago

Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

Rampageusa May. 12 at 9:55 PM

$WOK eventually this low floaters can do weird 100/200 like few others did $DRUG, $SMX ..many to name

1 · Reply

Aaronwasinger May. 12 at 2:35 PM

$DRUG $ERNA $TC

0 · Reply

CarlPhilipTrading May. 12 at 2:34 PM

$TC will go huge like $ERNA or $DRUG in 2024. TC super low float ww

0 · Reply

Rampageusa May. 8 at 5:32 PM

$AEHL the way they are playing seems 1000% ah hrs to 5/with multiple long halts till 3.00pm close..my opinion as I have seen such things for $DRUG and other tickers jn history..

0 · Reply

TheRealShortSqueezy May. 8 at 3:15 PM

0 · Reply

tupelo3 May. 7 at 9:42 PM

$DRUG anyone find it strange that $DRUG is providing earnings on a Friday after the close?

0 · Reply

BodhiJR May. 7 at 7:50 PM

0 · Reply

Taylormax May. 7 at 10:57 AM

0 · Reply

Trick2MoneyisHavingSum May. 5 at 11:47 AM

$SDOT .529 vwap, then 1 billion traded $DRUG $NUKK

0 · Reply

InvestingSpaceman May. 4 at 9:35 PM

$HKD $DRUG $GME

0 · Reply

ElginOnST May. 4 at 3:48 PM

$SKK $AIOS $AKAN $DRUG $IPST - told yall on Friday. Ripping on MASSIVE acquisition news today. Easy $10+ potential

1 · Reply

biotech May. 4 at 3:16 PM

$SGMO $SGMO BIGGEST #BEAR_TRAP EVER the #SQUEEZE will be #EPIC re $GME $DRUG $SGMO up 50% ... just 2 hours into the trading day with huge volume

0 · Reply

Doozio May. 4 at 2:30 PM

$XBI $AXSM BODI. That wen da huckleberries get $ETON n $DRUG z get $LGND ary ONTO 🐒🍌🧠⏰♾️

1 · Reply

ElginOnST May. 2 at 9:52 PM

$SKK - Small floats are hot 🔥 Keep an eye on this one. The float is TINY. 🔹️I, and a few others are seeing a ~267k free float. 🔹️No concerns of RS, since it was done last month. 🔹️Revenue is 3x the current MC. Undervalued. $AIOS $AKAN $DRUG $IPST

0 · Reply

DonVigo May. 2 at 6:09 PM

$SOUN People who are always saying "yes but", or I agree, but" cannot take pressure and will sell and bolt as soon as they make a small pile. Spund will undergo a massive SQUEEZE for days if we discipline ourselves. Look what happen to $AKAN, $DRUG and many more..

0 · Reply

CoffeeRocks May. 1 at 7:34 PM

$CODX $INO $TNON $IBRX $DRUG CODX BiG pump coming

3 · Reply

CoffeeRocks May. 1 at 12:28 PM

$AKAN $DRUG $RGC $VCX Will be satisfying to see that 0ne zero zero

0 · Reply

TheZymeth May. 1 at 7:00 AM

$AKAN same here! But mate, always remember that there is always an opportunity like this in the market. This run is still small compared to a kind of $DRUG $RGC $DFNS/NUKK $JNVR/$DFDV etc. Unless this will push til 900$, it will compete those monsters that we only see once in a decade! Congrats to the strong holders here! I am holding this since 7$ but never had such hard balls!

1 · Reply

LookaLike Apr. 30 at 6:40 PM

$XRTX hopefully next $DRUG

0 · Reply

Taylormax Apr. 30 at 5:00 PM

$AKAN Actually $LGHL is the next runner. I was right about $DRUG , and I'm right about $LGHL ! $AKAN can run another 200%

1 · Reply

CoffeeRocks Apr. 30 at 4:19 PM

$AKAN 50$ $DRUG

0 · Reply

Taylormax Apr. 30 at 1:56 PM

$AKAN Uuuummm.... $LGHL stock can do 5000% that $AKAN and $DRUG did. $LGHL has real fundamentals and a market cap in the thousands, sitting at 90 cents. Do your research. Shorts would get burned on $LGHL

0 · Reply

Market Cap	842.32M
Revenue (ttm)	0.00
Net Income (ttm)	-8.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	126,700
Avg Vol	167,888
Day's Range	N/A - N/A
Shares Out	9.73M
Stochastic %K	38%
Beta	-5.35
Analysts	Strong Sell
Price Target	$150.60